Emerging and Repurposed Therapeutics in Alcohol-Associated Liver Disease

This session surveys the expanding therapeutic landscape in alcohol-associated liver disease across the translational spectrum. Presentations span phase 2 trial data on incretin-based agents (zalfermin, cagrilintide, semaglutide) and target trial emulation of GLP-1 receptor agonists in decompensated cirrhosis, alongside preclinical studies of the repurposed PDE4 inhibitor roflumilast and examination of Rifaximin's potential to impact the microbiome to reduce fibrosis progression in ALD. Additional talks examine pharmacologic management of alcohol use disorder and its downstream hepatic impact, and the effect of alcohol-associated hepatitis on terlipressin response in hepatorenal syndrome. Through early-phase and preclinical work, animal models, and exploratory and retrospective analyses, these studies highlight both novel and repurposed agents and the evolving evidence base guiding their potential clinical application.